ARVN News and Press, Arvinas Inc. From 08/05/21

NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate ...

ARVN is a pioneering protein degrader biopharma with strong early data. Recently, Pfizer inked a $2bn deal with the company for just one of its assets. The stock looks very promising despite its 52-week highs. For further details see: Arvinas: Tremendous Value Increase W...

Koonsiri Boonnak/iStock via Getty Images GM (GM) took its turn in the spotlight during Friday's midday action. The carmaker announced a recall of its Chevy Volt electric vehicles due to fire concerns. Meanwhile, earnings news remained a key driver in intraday trading. Both South State (SSB) a...

Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...

Shares of Arvinas (NASDAQ: ARVN) rallied nearly 10% during Thursday's trading session, in response to the announcement of a new collaboration with drug giant Pfizer (NYSE: PFE) . The two companies will co-develop and then co-market Arvinas' ARV-471, currently in trials as a ...

Arvinas (ARVN) perks up 3.8% premarket after collaborating with Pfizer (PFE) to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor ((ER)) protein degrader.Under the terms of the agreement, Pfizer will pay Arvinas $650M...

– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2 development for the treatment of patients with local...

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...

NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking c...

NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer...